Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.
Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.
Virus Res. 2021 Mar;294:198262. doi: 10.1016/j.virusres.2020.198262. Epub 2020 Dec 14.
Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.
新型冠状病毒肺炎（COVID-19）对公众健康构成了严重威胁。为缓解这一危机，比较药物对 COVID-19 的疗效具有指导意义。回顾性分析了 2020 年 1 月 27 日至 2020 年 3 月 21 日期间，333 例接受阿比多尔、皮质类固醇、羟氯喹、洛匹那韦/利托那韦或奥司他韦单药治疗，并有明确结局和血清学抗体检测结果的患者。羟氯喹组的住院时间明显短于阿比多尔组和皮质类固醇组。奥司他韦组的住院时间明显短于阿比多尔、皮质类固醇和洛匹那韦/利托那韦组。羟氯喹组的 IgM 滴度明显高于其他四组，IgG 水平明显高于阿比多尔、洛匹那韦/利托那韦和奥司他韦组。我们的研究结果表明，羟氯喹可能具有有效治疗 COVID-19 的潜力，而奥司他韦在联合治疗中应谨慎考虑。
